OTUD5 and hepatocellular carcinoma: Our results indicated that MG132 treatment markedly reversed the OTUD5 knockdown-induced SLC38A1 downregulation in HCC cells (P < 0.05, Fig. 6A and Supplementary Fig. 4A).